The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.
Click on the button below to create your account and get immediate access to thousands of articles.
Tasly remains China's 2019 National Tech Innovation Demonstration Enterprise
Tasly Holding Group, one of China's leading pharmaceuticals companies, has recently passed through the country's review of National Technology Innovation Demonstration Enterprise in 2019, thanks to its continuous innovations made in the recent years.
August15,2019
Tasly in cooperation with Arbor on T89 R&D and marketing
Tasly Pharmaceutical Group Co., Ltd. (referred to as “Tasly”) and the US-based drug maker Arbor Pharmaceuticals, Inc. (referred to as “Arbor”) announced on Sep. 6 comprehensive cooperation in the R&D and marketing of T89 in the States.
September09,2018
Tasly invests in Mesoblast, introduces two stem cell products
Tasly Pharmaceutical Group CO.,LTD (600535.SH) announced that it had inked investment agreement and product development commercialization agreement with Mesoblast, the world's leading stem cell R&D company.
July18,2018
If you have any questions, please enter them in the box below.
Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.
Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.
